Inactive Instrument

Freeline Therapeutics Holdings plc




Biotechnology & Medical Research

Delayed Nasdaq 03:37:21 2024-02-16 pm EST 5-day change 1st Jan Change
6.48 USD -.--% Intraday chart for Freeline Therapeutics Holdings plc -.--% +1.73%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Syncona’s Takeover of Freeline Therapeutics Becomes Effective MT
Freeline Therapeutics Holdings plc Announces Resignation of Julia Gregory, Martin Andrews, Jeffrey Chodakewitz, Colin Love and Paul Schneider from the Board CI
Freeline Therapeutics Holdings plc(NasdaqCM:FRLN) dropped from NASDAQ Composite Index CI
Syncona Investment Management Limited completed the acquisition of the remaining 42.08% stake in Freeline Therapeutics Holdings plc. CI
Freeline shareholders approve Syncona acquisition AN
Freeline Therapeutics' Shareholders Approve Acquisition by Syncona MT
Syncona says Freeline trial for Gaucher disease treatment positive AN
European Equities Traded in the US as American Depositary Receipts Gain Friday MT
Freeline Therapeutics Holdings plc Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
HC Wainwright Downgrades Freeline Therapeutics to Neutral From Buy, Adjusts Price Target to $6.50 From $15 MT
Sector Update: Health Care Stocks Advance Late Afternoon MT
Sector Update: Health Care Stocks Higher in Afternoon Trading MT
FTSE 100 Closes Down 0.17% After Autumn Statement DJ
Syncona agrees to buyout deal with Freeline Therapeutics AN
Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday MT
Sector Update: Health Care MT
Syncona to Take Over Freeline Therapeutics MT
Freeline Therapeutics to be Acquired by Syncona for $28.3 Million MT
ADRs End Higher, Yoshitsu Co. Ltd. Climbs 19.2% DJ
ADRs Advance; Freeline Therapeutics Holdings Climbs 30% DJ
Freeline Therapeutics Holdings plc Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate CI
Freeline Therapeutics Says FLT201 Showed 'Substantial' Drop in Gaucher Disease Biomarker in First Patient of Phase 1/2 Study MT
FTSE 100 Closes Down 1.1% on Middle East Tensions DJ
Wedbush Downgrades Freeline Therapeutics to Neutral From Outperform, Cuts Price Target to $5 From $8 MT
Syncona Submits Takeover Bid for Freeline Therapeutics MT
Chart Freeline Therapeutics Holdings plc
More charts
Freeline Therapeutics Holdings plc is a United Kingdom-based clinical-stage biotechnology company. The Company is developing transformative adeno-associated virus (AAV) vector-mediated gene therapies. It is focused on improving patient lives through one-time treatments for chronic debilitating diseases. It uses its rationally designed AAV vector and capsid (AAVS3), along with promoters and transgenes, to deliver a functional copy of a therapeutic gene into human liver cells, thereby expressing a persistent functional level of the missing or dysfunctional protein into the patient's bloodstream. Therapeutic AAV vectors consist of two main components, the capsid and the expression cassette (that contains the gene and the promoter). The Company is advancing clinical programs in Fabry disease and Gaucher disease Type 1. The Company's pipeline includes Fabry Disease FLT190 for the treatment of Fabry disease and Gaucher Disease FLT201 for the treatment of type 1 Gaucher disease.
More about the company
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.